Capricor Therapeutics (CAPR) is a clinical-stage San Diego biotechnology company developing cell- and exosome-based therapies, led by deramiocel, an investigational treatment for Duchenne muscular dystrophy aimed at preserving upper-limb function in patients older than nine. Shares rose 3.01% on Tuesday to $8.55, up from the previous close of $8.30, confirming an upward move during the regular session. There was no fresh company announcement behind the advance. Instead, the stock is rebounding from a sharp three-session selloff as investors square positions in front of a regulatory decision expected within days.
The dominant force in Capricor's price action is the FDA's Nov. 22 target action date on the Biologics License Application for deramiocel. The company confirmed on its Nov. 10 quarterly call that the application sits in its final review stages and that all requested information, including a roughly 30,000-page major amendment, has been submitted.
The stakes are unusually high because the review is a second attempt. The FDA issued a complete response letter in July 2025, and an advisory committee voted 9-3 in July 2026 that evidence did not support effectiveness for DMD-related cardiomyopathy — a vote that did not address HOPE-3's primary endpoint of upper-limb function, which the trial met with a statistically significant 1.1-point difference versus placebo (p=0.029). With the decision just five days out, small incremental buying can move the stock meaningfully, and Tuesday's gain is consistent with pre-event positioning rather than a fundamental re-rating.
Context matters here. Capricor peaked at $11.22 on Nov. 11, then fell 8.7% on Nov. 12, 6.9% on Nov. 13, and 12.9% on Nov. 16 to close at $8.30 — a roughly 26% drawdown in three sessions. Tuesday's recovery from an intraday low near $8.21 reads as dip-buying into a known catalyst rather than a new information event.
Analyst views remain sharply divergent. Oppenheimer reiterated an Outperform rating and $54 target, arguing the HOPE-3 data, open-label extension results, and more than 900 robustness analyses support approval, with the stock potentially reaching $50 on a positive decision. Roth Capital raised its target to $10.50 from $7 but kept a Neutral rating, assigning 25% odds to approval and 75% to a delay or another complete response letter. That dispersion itself fuels two-way volatility.
Participation was elevated: more than 3.6 million shares traded by late afternoon against a 30-session average near 2.1 million. The action was company-specific, tied to a scheduled regulatory deadline rather than sector-wide momentum. Technically, the stock defended the $8.19–$8.30 zone that marked Monday's low and close, though it remains far below its 52-week high of $40.37 and down more than 70% year to date, with the Nov. 11 high of $11.23 standing as the nearest significant resistance. Market capitalization is roughly $500 million on about 58 million shares outstanding.
On a 0-to-100 scale, 0 means no meaningful news and a move that is normal for the stock, while 100 means transformative news paired with an extreme, rare price move. Capricor earns 16 out of 100.
The news component is moderate at best: the pending FDA decision is a genuinely major event for a company of this size, but nothing new was disclosed Tuesday, so the session reflected anticipation rather than fresh information. The price component is weak. At 3.01%, the move was only about half the stock's typical daily swing of roughly 6% over the past 60 sessions, and 45 of those 60 sessions produced equal or larger absolute changes. A modest event plus a routine move for this name yields a low score.
Everything hinges on the FDA. A decision on or before Nov. 22 — and, critically, the breadth of any approved label — will determine the next leg. A complete response letter would likely send shares toward cash value, roughly $198.5 million as of Sept. 30, or about $3.40 per share. Approval would shift focus to launch execution: the San Diego GMP facility can supply roughly 250 patients annually today, with a second-floor expansion targeted for validation in the first half of 2027 to support 2,000–2,500 patients. Investors also face the ongoing arbitration with NS Pharma, with a hearing expected in mid-2027, and a next earnings report expected around March 2027.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. Bots vary widely by strategy, timeframe, performance metrics, and the symbols they trade, so the page offers a practical way to compare approaches side by side. For readers tracking volatile biotech names like this one, reviewing the current leaders is a sensible next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on October 29, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The 10-day RSI Indicator for CAPR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In 71 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
CAPR moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.592). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (442.120).
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology